Pearl IRB is the first and only commercial IRB in the state of Indiana and one of the few in the Midwest. Gretchen Bowker and I identified a need in the clinical research industry for highly ethical, high value and efficient IRB reviews. Unfortunately, for many principal investigators (PIs), sponsors and CROs, the IRB review process is a difficult, mysterious and often very frustrating process.
While our first priority is of course to protect human subjects, we believe we can do that while also balancing the needs of institutions, sponsors and SMOs and CROs. Our company’s vision is to improve the clinical research process, which will lead to delivering therapeutics and diagnostics to patients sooner thus helping patients. Each of us has spent over 15 years in the industry employed by sponsors, therefore, we understand the sponsor research process and we have experienced firsthand the inefficiencies that keep patients waiting. I worked more than 15 years with Eli Lilly and Company in business roles, primarily in sales and marketing and also in operations and finance. Gretchen’s background includes over 25 years in regulatory affairs, and device and drug development.
To create Pearl IRB, we first assessed the market and studied the needs of the key players. We built this company to meet the needs that PIs, institutions, sponsors, and CROs have for independent and central IRB services. We have built an industry best practice quality system, created critical processes, and assembled a powerhouse team with expertise and experience in clinical research, IRBs, regulatory, and science. And we are relentlessly focused on delivering high quality service and output for our clients.
We engineered this company to deliver high quality service with uncompromising ethics. Ethics and patients are front and center, but also customer service and a high quality review process are really important to us. Our tagline and the three things we talk about are “Efficient. Ethical. Experienced.”
So let’s get started. Together we will drive enhanced efficiency and value in clinical research.